The European Medicines Agency (EMA) has published a new version of the “3-year work plan for the Quality domain” for the period January 2021 – December 2023. The GMDP IWG 3-year workplan is developed with a focus on the Network Strategy and Regulatory Science Strategy (RSS) goals, with a particular emphasis on supply chain integrity and resilience, product quality and the impact of new manufacturing technologies on the supply chain. The workplan includes specific activities to achieve an objective as well as including routine activities that contribute to the overall strategic objective.
Here is an overview of recently published plan:
| Document | Planned modification | Timeframe |
| GMP Guide: Chapter 4 (Documentation) | To provide the European Commission with a final text for the amended chapter in order to assure data integrity in the context of GMP. | Q1 2026 |
| GMP Guide: Annex 11 (Computerised Systems) | To provide the European Commission with a final text for the amended chapter in order to assure data integrity in the context of GMP. | Q1 2026 |
| Guidelines on GMP specific to ATMPS | Review the Guidelines in the light of new Annex 1 Manufacture of Sterile Medicinal Products and consider whether any updates are necessary. | Q4 2024 |
| GMP Guide: Annex 15 Qualification and Validation | Review the annex in the light of new technology in facilities, products and processes and consider whether any updates are necessary. Following up on LLE recommendations, consider whether the scope can be extended to APIs. | Q2 2024 |
| GMP Guide: Annex 16 Certification by a Qualified Person and Batch Release | Following up on LLE recommendations, consider revision of annex in order to provide additional guidance on batch traceability. | Q4 2024 |
| GMP Guide: Annex 4 (Manufacture of Veterinary Medicinal Products Other Than Immunological Veterinary Medicinal Products) | To review comments received from concept paper stakeholder consultation and draft an updated text. | Q4 2024 |
| GMP Guide: Annex 5 (Manufacture of Immunological Veterinary Medicinal Products) | To review comments received from concept paper stakeholder consultation and draft an updated text. | Q4 2024 |
| GMP Guide: GMP for Novel Veterinary Medicinal Products | To provide the European Commission with a final text. | Q4 2023 |
| GMP Guide: GMP for Autogenous Veterinary Vaccines | To provide the European Commission with a final text. | Q4 2023 |
| GMP and Marketing Authorisation Holders | To revise the paper in line with recommendations from the Nitrosamines LLE, to strengthen guidance for MAHs in terms of having adequate quality agreement with manufactures. | Q4 2023 |
| ICH Q13: Continuous Manufacturing | To support the EU members of the Expert Working Group (EWG) in developing the guideline. | Q4 2023 |
| VICH: GMP for API’s for Veterinary Medicines | To support the EU members of the Expert Working Group (EWG) in developing the guideline. | Q4 2023 |
| VICH: Other Q Guidelines for Veterinary Medicines | To support the EU members of the Expert Working Group (EWG) in any future adaptations of existing ICH Q Guidelines such as Q9/Q10 to veterinary medicines | Q4 2023 |
| Implementing Act: GMP for Veterinary Medicinal Products | To provide the European Commission with scientific advice on GMP standards to be incorporated into an implementing act on GMP for veterinary medicinal products. | Q4 2023 |
| Implementing Act: GMP for active substances for Veterinary Medicinal Products | To provide the European Commission with scientific advice on GMP standards to be incorporated into an implementing act on GMP for active substances for veterinary medicinal products. | Q4 2023 |
